More Company News

Allergy Therapeutics

£25.5m placing and open offer
02 Dec 2020Read More

Allergy Therapeutics

Business Finland funding for development of accelerated iTBS protocols
30 Nov 2020Read More

Allergy Therapeutics

Update on pilot study in severe depression
27 Nov 2020Read More

Allergy Therapeutics

Appointment of SVP of Clinical Development
23 Nov 2020Read More

Allergy Therapeutics

€0.9m purchase agreement for research prototypes
18 Nov 2020Read More

Allergy Therapeutics

US$100m equity investment by CPP Investments
17 Nov 2020Read More

Allergy Therapeutics

Appointment of CMO and Medical Director
17 Nov 2020Read More

Allergy Therapeutics

Intended cancellation of AIM listing
11 Nov 2020Read More

Allergy Therapeutics

Updated FY20 Outlook with net sales growth estimate
10 Nov 2020Read More

Allergy Therapeutics

CARMA Cell Therapies at SITC 2020
09 Nov 2020Read More

1 2 3 4 … 48
Return to Allergy Therapeutics
© 2019-20 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).